A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2002
11/21/2002	US20020173006 Generating chimeric zinc finger protein; obtain nucleotide sequences coding chimeric protein, transform cells, express nucleotide sequences, recover protein
11/21/2002	US20020173005 Nucleotide sequences coding polypeptide for use in the treatment of thrombosis
11/21/2002	US20020173004 Nucleotide sequences coding transport protein for use in the treatment of nervous system disorders
11/21/2002	US20020173002 Polypeptide for use in the diagnosis, prevention, and treatment of cancer, inflammation, and disorders associated with retinoid metabolism
11/21/2002	US20020173000 Nucleotide sequences coding polypeptide for use in treatment of alzeihmer's, parkinson, muscular, epilepsy, stroke, heart defects, amyotrophic lateral sclerosis, multiple sclerosis, inflammation, pain, cancer, and dietetic disorders
11/21/2002	US20020172999 Novel KIAA1061-like cell adhesion molecule-like proteins and polynucleotides encoding them
11/21/2002	US20020172995 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
11/21/2002	US20020172994 Nucleotide sequences coding polypeptides for use in the treatment of inflammation, tumors, arthritis, asthma, viral and inflammatory bowel diseases
11/21/2002	US20020172986 23228, a novel human tetraspanin family member and uses thereof
11/21/2002	US20020172985 Cassette for expressing a Toxoplasma gondii P30 protein
11/21/2002	US20020172984 Modulation of sctivity of transmembrane ligand; obtain sample containing tyrosine kinase, incubate with ligand, monitor bological activity, compare to control, adjustment in biological activity indicates modulator
11/21/2002	US20020172981 Nucleic acid molecules encoding human kinase and phosphatase homologues and uses therefor
11/21/2002	US20020172977 Forming a prion; obtain mutant prion, bind linker, monitor activity of prion
11/21/2002	US20020172976 P. gingivalis polynucleotides and uses thereof
11/21/2002	US20020172962 Generation of nucleotide sequence ligands; obtain nucleotide sequences mixture, separate nucleotide sequences, amplify nucleotide sequences, incubate with modulator, detect adjustment in binding activity
11/21/2002	US20020172959 Compositions and methods relating to lung specific genes and proteins
11/21/2002	US20020172958 Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries
11/21/2002	US20020172952 Compositions and methods for the therapy and diagnosis of lung cancer
11/21/2002	US20020172940 Methods and reagents for isolating biologically active peptides
11/21/2002	US20020172935 Methods of screening for compounds that modulate blood vessel formation from circulating endothelial cell precursors
11/21/2002	US20020172933 Protected during pasteurization stabilizers (monosaccharides, disaccharides, and oligosaccharides; or amino acids)
11/21/2002	US20020172717 Instilling microparticle or nanoparticle comprising biocompatible polymer and therapeutic agent into a patient's bladder such that portion of instilled microparticle or nanoparticles are localized to lymph nodes; releasing
11/21/2002	US20020172691 Use of a bacterial vaccinating preparation developed from a given bacterium of Bordetella genus for the preparation of protective antigen for man and animals against infections and toxic effects caused by bacterium of Bordetella genus
11/21/2002	US20020172687 Anti-Viral Treatment With Pertussis Toxin B Oligomer
11/21/2002	US20020172682 Using heat shock proteins to increase immune response
11/21/2002	US20020172681 Contacting Th2 cells with vMIP-I or an agonist or antagonist for modulating physiological signal specific to Th2 cells
11/21/2002	US20020172680 Diagnosis of metastatic cancer by the mts-1 gene
11/21/2002	US20020172679 Treatment of inflammatory bowel disease by inhibiting binding and/or signalling through alpha4beta7 and its ligands and MAdCAM
11/21/2002	US20020172678 For regulating cellular proliferation and chemotaxis
11/21/2002	US20020172675 Methods for detecting and inhibiting angiogenesis
11/21/2002	US20020172674 Administering formulation selected from a BAFF-R polypeptide or fragment; a chimeric molecule comprising a BAFF-R polypeptide or fragment fused to heterologous amino acid sequence; anti-BAFF-R antibody for inhibiting B-cell growth
11/21/2002	US20020172672 Serine protease and topical retinoid compositions useful for treatment of acne vulgaris and production of anti-aging effects
11/21/2002	US20020172670 Used to generate models for elucidating the structure of other polypeptides and for better identifying ligands capable of modulating mannosidase II activity
11/21/2002	US20020172669 Composition and method for lactose hydrolysis
11/21/2002	US20020172668 Recombinant antibacterial group iia phospholipase a2 and methods of use thereof
11/21/2002	US20020172667 To suppress the mutagenesis substances; health
11/21/2002	US20020172664 Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
11/21/2002	US20020172663 Localized myocardial injection method for treating ischemic myocardium
11/21/2002	US20020172662 Combination therapy (temozolomide and alpha-IFN) for advanced cancer
11/21/2002	US20020172661 For diagnosis, prevention, or treatment of diseases responsive to therapy with interferon- beta (IFN-beata)
11/21/2002	US20020172660 For therapy of cancer, viral infections
11/21/2002	US20020172659 Methods and materials for treating inflammatory diseases
11/21/2002	CA2449292A1 Dipeptide derivatives
11/21/2002	CA2447576A1 Use of hmg fragment as anti-inflammatory agents
11/21/2002	CA2447564A1 Nucleic acids and corresponding proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer
11/21/2002	CA2447518A1 Therapeutic use of rank antagonists
11/21/2002	CA2447444A1 Antisense permeation enhancers
11/21/2002	CA2447431A1 Inhibitors of receptor activator of nf-kb and uses thereof
11/21/2002	CA2447395A1 Targeted delivery of drugs for the treatment of parasitic infections
11/21/2002	CA2447343A1 Method to induce neovascular formation and tissue regeneration
11/21/2002	CA2447314A1 Arginine derivatives
11/21/2002	CA2447292A1 Peptide compounds for counteracting reactive oxygen species and free radicals
11/21/2002	CA2447118A1 Method and compositions for inhibiting thrombin-induced coagulation
11/21/2002	CA2447116A1 Methods for treating liver disease and liver damage with growth hormone and foxm1b
11/21/2002	CA2447110A1 Expression of membrane proteins using an adenylyl cyclase of mycobacterium tube rculosis
11/21/2002	CA2447052A1 Combined approach to treatment of cancer using a c-myc antisense oligomer
11/21/2002	CA2447050A1 Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
11/21/2002	CA2447004A1 Antisense modulation of ptp1b expression
11/21/2002	CA2446945A1 Method of preventing cell death using segments of neural thread proteins
11/21/2002	CA2446859A1 Transgenic animal model of bone mass modulation
11/21/2002	CA2446839A1 Method of modulating the activity of calcium channels in cardiac cells and reagents therefor
11/21/2002	CA2446821A1 Hbm variants that modulate bone mass and lipid levels
11/21/2002	CA2446806A1 Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
11/21/2002	CA2446720A1 High density lipoprotein-reactive peptides
11/21/2002	CA2446589A1 Methods for treating cancer
11/21/2002	CA2446582A1 Reagents and methods for modulating dkk-mediated interactions
11/21/2002	CA2446180A1 Cytokine polypeptides
11/21/2002	CA2446166A1 Isolated human secreted proteins nucleic acid molecules encoding human secreted proteins and uses thereof
11/21/2002	CA2446127A1 Destruction of prions using vibriolysin or variants thereof
11/21/2002	CA2446075A1 Novel maxizyme
11/21/2002	CA2446072A1 Treating epidermolysis bullosa with thymosin beta 4
11/21/2002	CA2445494A1 Optimization of the molecular properties and formulation of proteins delivered by inhalation
11/21/2002	CA2445366A1 Molecules for disease detection and treatment
11/21/2002	CA2443964A1 Use of osteopontin for the treatment and/or prevention of neurologic diseases
11/21/2002	CA2443160A1 Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof
11/21/2002	CA2442816A1 Human secreted proteins
11/21/2002	CA2442635A1 Gastrokines and derived peptides including inhibitors
11/21/2002	CA2429718A1 Human and non-human primate homologues of nkd protein, nucleic acid sequences encoding, and uses thereof
11/20/2002	WO2001091776A1 Hypotensive and hypertensive properties of renomedullar extracts
11/20/2002	WO2001091755A1 Active substance combination containing a compound with an opioid effect and at least one further compound of formula i
11/20/2002	EP1258532A1 Thermostable D-hydantoinase from Bacillus circulans and the application thereof
11/20/2002	EP1258530A2 Gaba-A receptor subunits (alpha-2, alpha-3, alpha-5, alpha -6, beta-2) and transfected cells expressing them
11/20/2002	EP1258529A2 FLIP Gene and FLIP Protein
11/20/2002	EP1258528A1 Expression of membrane proteins using an adenylyl cyclase of Mycobacterium tuberculosis
11/20/2002	EP1258497A2 Conjugates of factor VIII and a biocompatible polymer
11/20/2002	EP1258494A1 Multiprotein complexes from eukaryotes
11/20/2002	EP1258493A1 Cleavage and polyadenylation complex of precursor mRNA
11/20/2002	EP1258492A1 N-substituted oligomers and methods for their synthesis, e.g. polyglycine bearing nucleic acid bases
11/20/2002	EP1258491A1 Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
11/20/2002	EP1258253A1 Novel remedies with the use of beta3 agonist
11/20/2002	EP1258251A1 Compositions for preventing and treating digestive diseases
11/20/2002	EP1258250A1 Nerve protective drugs
11/20/2002	EP1257822A1 Her-2 binding antagonists
11/20/2002	EP1257669A1 Antisense modulation of e2f transcription factor 3 expression
11/20/2002	EP1257657A2 Autoregulatory expression vector for gene therapy
11/20/2002	EP1257653A2 Phosphodiesterase type 7b
11/20/2002	EP1257648A1 Antagonistic selective binding agents of osteoprotegerin binding protein
11/20/2002	EP1257646A2 Transporters and ion channels
11/20/2002	EP1257645A2 Fibroblast growth factor-23 molecules and uses thereof
11/20/2002	EP1257642A1 Partners of ptb1 domain of fe65, preparation and uses

1 ... 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 ... 3163